Hofmann M, Rest A, Hafner G, Tanner B, Brockerhoff P, Weilemann L S
Universitäts-Frauenklinik Mainz.
Anaesthesist. 1997 Aug;46(8):689-96. doi: 10.1007/s001010050455.
Two groups of 15 patients each with disseminated intravascular coagulation in association with septic disease were treated with low-molecular-weight heparin (lmw-heparin) in different dosages (group I: 1.5-5 IE/kg body weight (BW) per hour; group II: 8-15 IE/kg BW). We studied the levels of D-dimer, thrombin-antithrombin III complex (TAT), prothrombin fragments 1 and 2 (PTF), and global tests of coagulation like prothrombin time (PT), activated partial thromboplastin time (PTT), thrombin time (TT) and platelet count, plasminogen activation (PA) and fibrinogen concentration to estimate the success of heparin therapy in the two groups. TT and fibrinogen concentration were not suitable to follow the course of the coagulation disorder, PT, PTT, platelet count progressively PA, D-dimer, TAT, and PTF normalised progressively after heparinisation. However, only the last three parameters were sensitive enough to show different effects of variable dosages of lmw-heparin. D-dimer, TAT, and PTF levels declined in proportion with heparin concentrations, and thus appear to be the most useful parameters for monitoring the therapeutic effect of heparin in septic coagulopathies.
两组各15例伴有败血症的弥散性血管内凝血患者分别接受不同剂量的低分子量肝素(LMW-肝素)治疗(第一组:每小时1.5 - 5国际单位/千克体重(BW);第二组:8 - 15国际单位/千克体重)。我们研究了D-二聚体、凝血酶 - 抗凝血酶III复合物(TAT)、凝血酶原片段1和2(PTF)的水平,以及凝血的整体检测指标,如凝血酶原时间(PT)、活化部分凝血活酶时间(PTT)、凝血酶时间(TT)和血小板计数、纤溶酶原激活(PA)和纤维蛋白原浓度,以评估两组肝素治疗的效果。TT和纤维蛋白原浓度不适用于跟踪凝血障碍的进程,肝素化后PT、PTT、血小板计数、PA、D-二聚体、TAT和PTF逐渐恢复正常。然而,只有最后三个参数足够敏感,能够显示不同剂量的LMW-肝素的不同效果。D-二聚体、TAT和PTF水平随肝素浓度成比例下降,因此似乎是监测肝素治疗败血症性凝血病疗效最有用的参数。